Table 3.

Summary of recommendations

Guidelines	Population	Screening process				Treatment method	Treatment duration	Timing before immunosuppression
		History	TST	IGRA	CXR
ARA 20101	Biological therapy		X	X	X	Isoniazid*	6–9 months	1–2 months
Aguado et al 20093	Transplant recipients	X	X		X	Isoniazid	9 months	Before transplant
CDC 20169	Patients with HIV		X	X		Isoniazid	9 months	NS
WHO 201510	Low-middle income countries		X	X		Isoniazid	6 months	NS
Beglinger et al 200715	Biological therapy	X		X	X	Isoniazid OR rifampicin	NS	1 month
Cantini et al 201516	Biological therapy	X	X	X		Isoniazid	9 months	1 month
Doherty 200817	Patients with psoriasis	X	X		X	Isoniazid	9 months	1–2 months or longer
Duarte et al 201218	Biological therapy	X	X	X		Isoniazid	9 months	1–2 months
Fonseca et al 200819	Biological therapy	X	X		X	Isoniazid	6–9 months	1 month
Hodkinson et al 201320	Patients with rheumatoid arthritis	X	X	X	X	Isoniazid	9 months	1 month
Kavanagh et al 200821	Biological therapy	X	X		X	Isoniazid	9 months	Pre-immunosuppression
Keith et al 201422	Bullous dermatosis		X	X		NS	NS	NS
Koike et al 200723	Biological therapy	X	X		X	Isoniazid	NS	NS
Lichauco et al 200624	Biological therapy		X		X	Isoniazid	9 months	1 month
Salmon200225	Biological therapy		X		X	Rifampicin and pyrazinamide	2 months	3 weeks
Mir Viladrich et al 201626	Biological therapy	X	X	X		Isoniazid	9 months	4 weeks
Mok et al 201127	Biological therapy		X			Isoniazid	9 months	4 weeks
Nordgaard-Lassen et al 2012 28	Biological therapy			X		Isoniazid	9 months	4 weeks
BTS 200529	Biological therapy	X	X		X	Isoniazid	6 months	Concurrent
Smith et al 200930	Biological therapy			X	X	Isoniazid OR Isoniazid and rifampicin	6 months OR 3 months	2 months
Solovic et al 201031	Biological therapy	X	X	X	X	Isoniazid	9 months	4 weeks
Carrasoca et al 201632	Methotrexate therapy		X	X	X	Isoniazid	NS	NS
Bumbacea et al 201233	Transplant recipients		X	X		NS	NS	Before transplant
KDIGO 200934	Renal transplant	X	X			Isoniazid	9 months	NS
Meije et al 201435	Transplant recipients		X	X		Isoniazid	9 months	NS
EBPG 200236	Renal transplant recipients	X	X		X	Isoniazid	9 months	NS
Subramanian 201337	Transplant recipients	X	X	X	X	Isoniazid	9 months	Before or after transplant
Tomblyn et al 200938	SCT recipients	X	X	X		Isoniazid	9 months	NS
Pozniak et al 201139	Patients with HIV		X	X		Isoniazid	6 months	NS
SA 201040	Patients with HIV		X			Isoniazid	6 months	NS
Santin et al 201741	Patients with HIV	X	X	X		NS	NS	NS
	Biological therapy	X	X	X		NS	NS	NS
	Transplant recipients	X	X	X		NS	NS	NS
Al Jahdali et al 201042	Susceptible populations		X	X		Isoniazid	9 months	NS
ECDC 201143	Immunocompromised		X	X		NS	NS	NS
Mazurek et al 201044	Susceptible populations	X	X	X	X	NS	NS	NS
Taylor et al (CDC 2005)45	Susceptible populations	X	X	X		Isoniazid	NS	NS
CTC 200846	Immunocompromised		X	X		NS	NS	NS
Japanese Society for Tuberculosis 201447	Susceptible populations	X		X	X	Isoniazid	6–9 months	3 weeks before immunosuppression NS for transplant
NICE 201648	Susceptible populations	X	X	X		Isoniazid OR Isoniazid and rifampicin	6 months OR 3 months	NS

*Where isoniazid is used, it is always provided concurrently with pyridoxine prophylaxis.

ARA, Australian Rheumatological Association; BTS, British Thoracic Society; CDC, centre for disease control; CTC, Canadian Tuberculosis Committee; CXR, chest X-ray; EBPG, European Best Practice Guideline Expert Group on Renal Transplantation; ECDC, European Centre for Disease Prevention and Control; IGRA, interferon gamma release assay; KDIGO, Kidney Disease Improving Global Outcomes; NICE, National Institute for Health and Care Excellence; NS, not specified; SA, South Africa; SCT, Stem cell transplant, TST, tuberculin skin test.